Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23

A Cancer and Leukemia Group B Study

Krzysztof Mrózek, Kristiina Heinonen, David Lawrence, Andrew J. Carroll, Prasad R K Koduru, Kathleen W. Rao, Matthew P. Strout, Robert E. Hutchison, Joseph O. Moore, Robert J. Mayer, Charles A. Schiffer, Clara D. Bloomfield

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9;11)(p22;q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of French-American-British (FAB) M5 subtype in the t(9;11) group (83% v 43%, P = .006), the patients with t(9;11) did not differ significantly from patients with t(11q23) in terms of their presenting clinical or hematologic features. Patients with t(9;11) more frequently had an extra chromosome(s) 8 or 8q as secondary abnormalities (46% v 9%, P = .008). All patients received standard cytarabine and daunorubicin induction therapy, and most of them also received cytarabine-based intensification treatment. Two patients, both with t(9;11), underwent bone marrow transplantation (BMT) in first complete remission (CR). Nineteen patients (79%) with t(9;11) and 13 (57%) with t(11q23) achieved a CR (P = .13). The clinical outcome of patients with t(9;11) was significantly better: the median CR duration was 10.7 versus 8.9 months (P = .02), median event-free survival was 6.2 versus 2.2 months (P = .009), and median survival was 13.2 versus 7.7 months (P = .009). All patients with t(11q23) have died, whereas seven (29%) patients with t(9;11) remain alive in first CR. Seven of eight patients with t(9;11) who received postremission regimens with cytarabine at a dose of 100 (four patients) or 400 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed. In contrast, 7 (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at a dose 3 g/m2) (5 patients), or underwent BMT (2 patients) remain in continuous CR. We conclude that the outcome of adults with de novo AML and t(9;11) is more favorable than that of adults with other 11q23 translocations; this is especially true for t(9;11) patients who receive intensive postremission therapy.

Original languageEnglish (US)
Pages (from-to)4532-4538
Number of pages7
JournalBlood
Volume90
Issue number11
StatePublished - Dec 1 1997

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Leukemia
Chromosomes
Neoplasms
Bone
Daunorubicin
Chemotherapy
Bone Marrow Transplantation
Therapeutics
Chromosomes, Human, Pair 8
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23 : A Cancer and Leukemia Group B Study. / Mrózek, Krzysztof; Heinonen, Kristiina; Lawrence, David; Carroll, Andrew J.; Koduru, Prasad R K; Rao, Kathleen W.; Strout, Matthew P.; Hutchison, Robert E.; Moore, Joseph O.; Mayer, Robert J.; Schiffer, Charles A.; Bloomfield, Clara D.

In: Blood, Vol. 90, No. 11, 01.12.1997, p. 4532-4538.

Research output: Contribution to journalArticle

Mrózek, K, Heinonen, K, Lawrence, D, Carroll, AJ, Koduru, PRK, Rao, KW, Strout, MP, Hutchison, RE, Moore, JO, Mayer, RJ, Schiffer, CA & Bloomfield, CD 1997, 'Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B Study', Blood, vol. 90, no. 11, pp. 4532-4538.
Mrózek, Krzysztof ; Heinonen, Kristiina ; Lawrence, David ; Carroll, Andrew J. ; Koduru, Prasad R K ; Rao, Kathleen W. ; Strout, Matthew P. ; Hutchison, Robert E. ; Moore, Joseph O. ; Mayer, Robert J. ; Schiffer, Charles A. ; Bloomfield, Clara D. / Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23 : A Cancer and Leukemia Group B Study. In: Blood. 1997 ; Vol. 90, No. 11. pp. 4532-4538.
@article{d6bc47d7ae62446682967ed3650986ee,
title = "Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B Study",
abstract = "Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9;11)(p22;q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of French-American-British (FAB) M5 subtype in the t(9;11) group (83{\%} v 43{\%}, P = .006), the patients with t(9;11) did not differ significantly from patients with t(11q23) in terms of their presenting clinical or hematologic features. Patients with t(9;11) more frequently had an extra chromosome(s) 8 or 8q as secondary abnormalities (46{\%} v 9{\%}, P = .008). All patients received standard cytarabine and daunorubicin induction therapy, and most of them also received cytarabine-based intensification treatment. Two patients, both with t(9;11), underwent bone marrow transplantation (BMT) in first complete remission (CR). Nineteen patients (79{\%}) with t(9;11) and 13 (57{\%}) with t(11q23) achieved a CR (P = .13). The clinical outcome of patients with t(9;11) was significantly better: the median CR duration was 10.7 versus 8.9 months (P = .02), median event-free survival was 6.2 versus 2.2 months (P = .009), and median survival was 13.2 versus 7.7 months (P = .009). All patients with t(11q23) have died, whereas seven (29{\%}) patients with t(9;11) remain alive in first CR. Seven of eight patients with t(9;11) who received postremission regimens with cytarabine at a dose of 100 (four patients) or 400 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed. In contrast, 7 (64{\%}) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at a dose 3 g/m2) (5 patients), or underwent BMT (2 patients) remain in continuous CR. We conclude that the outcome of adults with de novo AML and t(9;11) is more favorable than that of adults with other 11q23 translocations; this is especially true for t(9;11) patients who receive intensive postremission therapy.",
author = "Krzysztof Mr{\'o}zek and Kristiina Heinonen and David Lawrence and Carroll, {Andrew J.} and Koduru, {Prasad R K} and Rao, {Kathleen W.} and Strout, {Matthew P.} and Hutchison, {Robert E.} and Moore, {Joseph O.} and Mayer, {Robert J.} and Schiffer, {Charles A.} and Bloomfield, {Clara D.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "90",
pages = "4532--4538",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23

T2 - A Cancer and Leukemia Group B Study

AU - Mrózek, Krzysztof

AU - Heinonen, Kristiina

AU - Lawrence, David

AU - Carroll, Andrew J.

AU - Koduru, Prasad R K

AU - Rao, Kathleen W.

AU - Strout, Matthew P.

AU - Hutchison, Robert E.

AU - Moore, Joseph O.

AU - Mayer, Robert J.

AU - Schiffer, Charles A.

AU - Bloomfield, Clara D.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9;11)(p22;q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of French-American-British (FAB) M5 subtype in the t(9;11) group (83% v 43%, P = .006), the patients with t(9;11) did not differ significantly from patients with t(11q23) in terms of their presenting clinical or hematologic features. Patients with t(9;11) more frequently had an extra chromosome(s) 8 or 8q as secondary abnormalities (46% v 9%, P = .008). All patients received standard cytarabine and daunorubicin induction therapy, and most of them also received cytarabine-based intensification treatment. Two patients, both with t(9;11), underwent bone marrow transplantation (BMT) in first complete remission (CR). Nineteen patients (79%) with t(9;11) and 13 (57%) with t(11q23) achieved a CR (P = .13). The clinical outcome of patients with t(9;11) was significantly better: the median CR duration was 10.7 versus 8.9 months (P = .02), median event-free survival was 6.2 versus 2.2 months (P = .009), and median survival was 13.2 versus 7.7 months (P = .009). All patients with t(11q23) have died, whereas seven (29%) patients with t(9;11) remain alive in first CR. Seven of eight patients with t(9;11) who received postremission regimens with cytarabine at a dose of 100 (four patients) or 400 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed. In contrast, 7 (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at a dose 3 g/m2) (5 patients), or underwent BMT (2 patients) remain in continuous CR. We conclude that the outcome of adults with de novo AML and t(9;11) is more favorable than that of adults with other 11q23 translocations; this is especially true for t(9;11) patients who receive intensive postremission therapy.

AB - Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9;11)(p22;q23) have a better prognosis than those with translocations between 11q23 and other chromosomes, we compared response to therapy and survival of 24 adult de novo AML patients with t(9; 11) with those of 23 patients with other 11q23 translocations [t(11q23)]. Apart from a higher proportion of French-American-British (FAB) M5 subtype in the t(9;11) group (83% v 43%, P = .006), the patients with t(9;11) did not differ significantly from patients with t(11q23) in terms of their presenting clinical or hematologic features. Patients with t(9;11) more frequently had an extra chromosome(s) 8 or 8q as secondary abnormalities (46% v 9%, P = .008). All patients received standard cytarabine and daunorubicin induction therapy, and most of them also received cytarabine-based intensification treatment. Two patients, both with t(9;11), underwent bone marrow transplantation (BMT) in first complete remission (CR). Nineteen patients (79%) with t(9;11) and 13 (57%) with t(11q23) achieved a CR (P = .13). The clinical outcome of patients with t(9;11) was significantly better: the median CR duration was 10.7 versus 8.9 months (P = .02), median event-free survival was 6.2 versus 2.2 months (P = .009), and median survival was 13.2 versus 7.7 months (P = .009). All patients with t(11q23) have died, whereas seven (29%) patients with t(9;11) remain alive in first CR. Seven of eight patients with t(9;11) who received postremission regimens with cytarabine at a dose of 100 (four patients) or 400 mg/m2 (2 patients) or who did not receive postremission therapy (2 patients) have relapsed. In contrast, 7 (64%) of 11 patients who received intensive postremission chemotherapy with high-dose cytarabine (at a dose 3 g/m2) (5 patients), or underwent BMT (2 patients) remain in continuous CR. We conclude that the outcome of adults with de novo AML and t(9;11) is more favorable than that of adults with other 11q23 translocations; this is especially true for t(9;11) patients who receive intensive postremission therapy.

UR - http://www.scopus.com/inward/record.url?scp=1842289846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842289846&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 4532

EP - 4538

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -